{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:41:03Z","timestamp":1740152463806,"version":"3.37.3"},"reference-count":30,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key Medical and Health Projects in Xiamen","award":["3502Z20209002","2020J011220","81772893","2019-ZQNB-25"],"award-info":[{"award-number":["3502Z20209002","2020J011220","81772893","2019-ZQNB-25"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["3502Z20209002","2020J011220","81772893","2019-ZQNB-25"],"award-info":[{"award-number":["3502Z20209002","2020J011220","81772893","2019-ZQNB-25"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["3502Z20209002","2020J011220","81772893","2019-ZQNB-25"],"award-info":[{"award-number":["3502Z20209002","2020J011220","81772893","2019-ZQNB-25"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Commission Young and Middle-Aged Talents Training Project of Fujian Health Commission","award":["3502Z20209002","2020J011220","81772893","2019-ZQNB-25"],"award-info":[{"award-number":["3502Z20209002","2020J011220","81772893","2019-ZQNB-25"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Oncology"],"published-print":{"date-parts":[[2022,3,21]]},"abstract":"<jats:p>Purpose. To explore the efficacy and safety of adding olanzapine (5\u2009mg or 10\u2009mg) to 5-hydroxytryptamine type 3 receptor antagonists (5-HT3 RA), neurokinin-1 receptor antagonists (NK1 RA), and dexamethasone for nausea and vomiting in patients with nasopharyngeal carcinoma (NPC) receiving cisplatin-based concurrent chemoradiotherapy. Methods. Patients receiving olanzapine 5\u2009mg or 10\u2009mg combined with 5-HT3 RA, NK1 RA, and dexamethasone during the cisplatin-based concurrent chemoradiotherapy were included. The primary endpoint was the complete response (CR) (no vomiting) rate, and the secondary endpoint was the incidence of no nausea. Results. A total of 150 chemotherapy cycles were administrated for 88 patients (75 in the olanzapine 5\u2009mg group and 75 in the olanzapine 10\u2009mg group). The proportions of CR in the olanzapine 5\u2009mg group were comparable to those in the olanzapine 10\u2009mg group in acute (93.3% vs. 94.7%, <jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>=<\/a:mo>\n                        <a:mn>0.731<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>), delayed (76% vs. 78.7%, <jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                        <c:mo>=<\/c:mo>\n                        <c:mn>0.697<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>), and overall phase (73.3% vs. 77.3%, <jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                        <e:mo>=<\/e:mo>\n                        <e:mn>0.570<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>). Moreover, no nausea rates were also comparable between the two groups in acute (76% vs. 78.7%, <jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>=<\/g:mo>\n                        <g:mn>0.697<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>), delayed (54.7% vs. 60%, <jats:inline-formula>\n                     <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\">\n                        <i:mi>P<\/i:mi>\n                        <i:mo>=<\/i:mo>\n                        <i:mn>0.509<\/i:mn>\n                     <\/i:math>\n                  <\/jats:inline-formula>), and overall period (50.7% vs. 57.3%, <jats:inline-formula>\n                     <k:math xmlns:k=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M6\">\n                        <k:mi>P<\/k:mi>\n                        <k:mo>=<\/k:mo>\n                        <k:mn>0.111<\/k:mn>\n                     <\/k:math>\n                  <\/jats:inline-formula>). Regarding the adverse effects, the incidence of somnolence in the 10\u2009mg group (58.6%) was significantly higher than that in the 5\u2009mg group (41.3%) (<jats:inline-formula>\n                     <m:math xmlns:m=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M7\">\n                        <m:mi>P<\/m:mi>\n                        <m:mo>=<\/m:mo>\n                        <m:mn>0.034<\/m:mn>\n                     <\/m:math>\n                  <\/jats:inline-formula>), while constipation (20.0% vs. 24.0%, <jats:inline-formula>\n                     <o:math xmlns:o=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M8\">\n                        <o:mi>P<\/o:mi>\n                        <o:mo>=<\/o:mo>\n                        <o:mn>0.554<\/o:mn>\n                     <\/o:math>\n                  <\/jats:inline-formula>) and hiccups (9.3% vs. 10.6%, <jats:inline-formula>\n                     <q:math xmlns:q=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M9\">\n                        <q:mi>P<\/q:mi>\n                        <q:mo>=<\/q:mo>\n                        <q:mn>0.785<\/q:mn>\n                     <\/q:math>\n                  <\/jats:inline-formula>) rates were comparable in two groups. Conclusions. Patients receiving olanzapine plus standard antiemetic therapy has excellent antiemetic effect in NPC patients receiving cisplatin-based concurrent chemoradiotherapy, and patients with olanzapine 5\u2009mg have a similar antiemetic effect and lower adverse effects compared with those with olanzapine 10\u2009mg.<\/jats:p>","DOI":"10.1155\/2022\/9984738","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:20:11Z","timestamp":1647883211000},"page":"1-7","source":"Crossref","is-referenced-by-count":1,"title":["Olanzapine 5\u2009mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0313-1789","authenticated-orcid":true,"given":"Jun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Head and Neck Oncology, Department of Radiation Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3012-1597","authenticated-orcid":true,"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1670-4558","authenticated-orcid":true,"given":"Li-E","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4391-8706","authenticated-orcid":true,"given":"Qin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-2614","authenticated-orcid":true,"given":"San-Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"volume-title":"NCCN clinical practice guidelines in oncology. Head-and-neck cancers, version 3, 2021","author":"NCCN","key":"2"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03237"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905287"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30104-9"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00075-9"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0105"},{"issue":"5","key":"8","first-page":"637","article-title":"Practical management of chemotherapy-induced nausea and vomiting","volume":"19","author":"W. Wiser","year":"2005","journal-title":"Oncology"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.3390\/nu9080867"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.15.6207"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32099"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"13","article-title":"NCCN clinical practice guidelines in oncology","author":"NCCN","year":"2021","journal-title":"Antiemesis"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.08.048"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725"},{"issue":"1","key":"18","first-page":"24","article-title":"Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting","volume":"5","author":"M. V. Brafford","year":"2014","journal-title":"Journal of the Advanced Practitioner in Oncology"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01570-3"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.05.003"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1200-4"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.10.007"},{"issue":"6","key":"24","first-page":"1523","article-title":"Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race","volume":"11","author":"B. A. Hassan","year":"2010","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.12788\/jcso.0245"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-131"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34618-x"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2020.10.012"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2020.10.014"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjorl.2019.04.008"}],"container-title":["Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/9984738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/9984738.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2022\/9984738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:20:22Z","timestamp":1647883222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/jo\/2022\/9984738\/"}},"subtitle":[],"editor":[{"given":"Weiren","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":30,"alternative-id":["9984738","9984738"],"URL":"https:\/\/doi.org\/10.1155\/2022\/9984738","relation":{},"ISSN":["1687-8469","1687-8450"],"issn-type":[{"type":"electronic","value":"1687-8469"},{"type":"print","value":"1687-8450"}],"subject":[],"published":{"date-parts":[[2022,3,21]]}}}